Melissa M St Amand et al.
Biotechnology and bioengineering, 111(10), 1957-1970 (2014-04-15)
N-linked glycan distribution affects important end-use characteristics such as the bioactivity and efficacy of many therapeutic proteins, (including monoclonal antibodies), in vivo. Yet, obtaining desired glycan distributions consistently during batch-to-batch production can be challenging for biopharmaceutical manufacturers. While an appropriately